idiopathic pulmonary fibrosis
Conditions
Interventions
IPF patient group:None
Validation group:None
Sponsors
Shanghai Pulmonary Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.>=18 years old, male or female; 2.The condition is stable according to the diagnostic criteria of different types of interstitial lung diseases and the diagnosis is determined by MDT discussion Patients with IPF. No acute exacerbation was determined by the investigators; 3.Regardless of whether the patient received antifibrotic therapy or other treatments; 4.Participants who are willing to participate in the study and sign the informed consent, have the ability of autonomous behavior, have good compliance, and are willing to follow the program Ask for tests and regular follow-up;
Exclusion criteria
Exclusion criteria: 1.Diagnosed by clinical doctors with diseases as follows: pulmonary sarcoidosis, lung cancer with ILD at enrollment, cryptogenic organizing pneumonia or radiation induced lung injury, chronic obstructive pulmonary disease (copd), bronchial asthma, infectious lung disease; 2.Patients with other clinically significant abnormalities in the lungs that the investigators determined might affect the study results (e.g., pulmonary embolism, pneumothorax, etc.); 3.Significant extrapulmonary physical or pathological limitations (e.g., chest wall malformations, massive pleural effusion, muscle weakness, diaphragmatic paralysis, etc.); 4.Patients with significant systemic and other diseases that the investigator determines may have an impact on the results of the study (such as severe neurological or cardiovascular diseases); 5.Patients with difficulty in follow-up or who are determined by the researchers to be unable to complete the relevant study (such as pregnant women);
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1-year IPF all-cause mortality; | — |
Secondary
| Measure | Time frame |
|---|---|
| 2-year IPF all-cause mortality;3-year IPF all-cause mortality;First acute exacerbation of IPF;IPF-related event mortality rate; | — |
Countries
China
Contacts
Public ContactQian Yao
Shanghai Pulmonary Hospital
Outcome results
None listed